• PDF: Delivered by email usually within 4 to 8 UK business hours.

Germany Pharmaceuticals and Healthcare Report Q2 2013

  • Publication Date:April 2013
  • Publisher:Business Monitor
  • Product Type: Report
  • Pages:105
  • ISBN:180650

Germany Pharmaceuticals and Healthcare Report Q2 2013

Includes 3 FREE quarterly updates

BMI View: We continue to believe the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) legislation -
which mandates that cost-effectiveness criteria-based system be used in negotiations of prices of new
drugs between drug companies and health insurers - will constrict drug companies' revenue-earning
opportunities in Germany. Although we additionally caution that the reform will hamper new drug
launches in the country and also lead to further job losses in the industry, Germany will remain one of the
largest pharmaceutical markets globally.
Headline Expenditure Projections
• Pharmaceuticals: EUR38.65bn (US$49.08bn) in 2012 to EUR37.72bn (US$47.15bn) in 2013;
-2.4% in local currency terms and -3.9% in US dollar terms. Local currency forecast slightly
lower from Q113, on account of downward pressures on pharmaceutical spending.
• Healthcare: EUR306.00bn (US$388.63bn) in 2012 to EUR313.76bn (US$392.20bn) in 2013;
+2.5% in local currency terms and +0.9% in US dollar terms. Local currency forecast slightly
lower from Q113, on account of austerity measures.
Executive Summary 7
SWOT Analysis 9
Germany Pharmaceuticals And Healthcare Industry SWOT 9
Germany Political SWOT 10
Germany Economic SWOT 10
Germany Business Environment SWOT 11
Pharmaceutical Risk/Reward Ratings 12
Table: Western Europe Pharmaceutical Risk/Reward Ratings, Q213 12
Rewards 13
Risks 14
Germany - Market Summary 15
Regulatory Regime 16
Table: BfArM Drug Registration Activity, 2006-10 16
Intellectual Property Regime 18
Pricing Regime 19
Table: Price Build-Up In The German Pharmaceutical Market 20
Pricing Regime Developments 20
Table: Selected AMNOG Drug Assessments 22
Reimbursement Regime 24
Table: Top 10 GKV Selling Drug Brands, 2009-2010 (EURmn) 24
Reimbursement Developments 26
Parallel Imports 28
Industry Developments 29
Epidemiology 29
Healthcare Sector 30
Health Insurance 30
Healthcare Sector Reforms 31
Research & Development 32
Biotechnology Sector 36
Table: Biotechnology Sector, 2008-09 36
Clinical Trials 38
Industry Forecast Scenario 39
Pharmaceutical Market Forecast 39
Table: Germany Pharmaceutical Sales, Historical Data and Forecasts 41
Healthcare Market Forecast 42
Table: Germany Healthcare Expenditure Trends, Historical Data and Forecasts 43
Table: Germany Government Healthcare Expenditure Trends, Historical Data and Forecasts 43
Table: Germany Private Healthcare Expenditure Trends, Historical Data and Forecasts 44
Key Growth Factors - Macroeconomic 45
Table: Germany Long-Term Macroeconomic Forecasts 47
Prescription Drug Market Forecast 48
Table: Retail Pharmaceutical Expenditure, 2003-10 (EURbn) 48
Table: Retail Pharmaceutical Expenditure, 2003-10 (Packages, ms) 49
Table: Retail Pharmaceutical Expenditure, 2003-10 (Average Price per Pack, EUR) 49
Table: Germany Prescription Drug Market Indicators, Historical Data and Forecasts 50
Patented Drug Market Forecast 51
Table: Germany Patented Drug Market Indicators, Historical Data and Forecasts 52
Generic Drug Market Forecast 53
Table: Germany Generics Drug Market Indicators, Historical Data and Forecasts 55
OTC Medicine Market Forecast 56
Table: Germany Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 57
Pharmaceutical Trade Forecast 58
Table: Germany Pharmaceutical Trade Data And Forecasts (US$mn) 59
Table: Germany Pharmaceutical Trade Data And Forecasts (EURmn) 59
Other Healthcare Data 60
Key Risks To BMI's Forecast Scenario 61
Competitive Landscape 62
Pharmaceutical Industry 62
Table: Pharmaceutical Production, 1990-10 62
Table: Leading German Pharmaceutical Companies 64
Company Developments 64
Wholesale Sector 65
Table: Members of the Association of Pharmaceutical Wholesalers (PHAGRO), 2012 65
Wholesale Sector Developments 67
Retail Sector 68
Online Pharmacies 70
Company Profiles 73
Local Companies 73
Bayer HealthCare 73
Boehringer Ingelheim 77
STADA Arzneimittel 81
Grünenthal 84
Merck KGaA 85
Multinational Companies 88
GlaxoSmithKline (GSK) 88
Pfizer 90
Novartis 92
Sanofi 93
Merck & Co 95
Table: Population By Age Group, 1990-2020 (‘000) 96
Table: Population By Age Group, 1990-2020 (% of total) 97
Table: Key Population Ratios, 1990-2020 98
Table: Rural And Urban Population, 1990-2020 98
Glossary 99
BMI Methodology 101
How We Generate Our Pharmaceutical Industry Forecasts 101
Risk/Reward Ratings Methodology 102
Ratings Overview 102
Table: Pharmaceutical Business Environment Indicators 103
Weighting 104
Table: Weighting Of Components 104
Sources 104
+44 20 8816 8548

Ask a question about Germany Pharmaceuticals and Healthcare Report Q2 2013

Enter the characters you see in the picture below
Captcha